Genomma Lab Announces Its 2010 Earnings Guidance
S.A.B. de C.V. (BMV: LAB) (“Genomma Lab” or “the Company”) announces today its
2010 earnings guidance.
Genomma Lab expects net sales growth in the range of 42% to 45% for the
full year of 2010, excluding possible acquisitions, and an EBITDA margin
between 25.0% and 26.0%, from 2009 year-end results which we expect to be
above our last issued guidance.
The Company’s estimates are based on organic growth in base line products,
the full year effect in sales of products launched or acquired during 2009,
growth in international operations as well as product line extensions and new
brands in existing and new categories.
Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing
pharmaceutical and personal care products companies in
Lab develops, sells and markets a broad range of premium branded products,
many of which are leaders in the categories in which they compete in terms of
sales and market share. The Company has a sound business model through a
unique combination of a new product development process, consumer oriented
marketing, a broad retail distribution network and a low-cost, highly flexible
supply chain operating model.
Contact: Oscar Villalobos Tel: +52 (55) 5081- 0000 ext. 4250 E-mail: firstname.lastname@example.org In New York: i-advize Corporate Communications, Inc. Tel: (212) 406-3695 E-mail: email@example.com
SOURCE Genomma Lab Internacional, S.A.B. de C.V.